Company Encyclopedia
View More
name
Psyence Biomedical
PBM.US
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care.
1.884 T
PBM.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Psyence BioMed Reports Phase IIb Trial Progress and Strengthened Cash Position

    Psyence Biomedical Ltd. announced progress in its Phase IIb trial for psilocybin-assisted psychotherapy in palliative care, with initial patient dosing in Australia. The company enhanced its manufacturing capabilities and ended 2025 debt-free with $9 million in cash reserves. For 2026, Psyence plans to accelerate trial enrollment, expand manufacturing, pursue longevity-focused indications, and explore strategic partnerships.

    Reuters·
    US
    PBM
    +0.68%
    Reuters·
    US
    PBM
    +0.68%

    Psyence BioMed Launches Psilocybin Longevity Research Program

    Psyence Biomedical Ltd. has launched a psilocybin longevity research program in South Africa, aiming to study psilocybin's effects on aging markers. Led by Dr. Tanya Calvey, the project is in its early stages, with progress expected next year post-ethics approval. No scientific results are available yet. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    PBM
    +0.68%
    Reuters·
    US
    PBM
    +0.68%

    Psyence BioMed Takes Minority Stake in PsyLabs to Boost African Ibogaine Operations

    Psyence BioMed has made a strategic equity investment in PsyLabs, enhancing its African ibogaine operations. This move positions Psyence BioMed as the sole publicly listed psychedelics company with active operations in Africa, strengthening its supply chain and providing early access to pipeline products and intellectual property development amid rising global demand for psychedelic APIs.

    Reuters·
    US
    PBM
    +0.68%
    Reuters·
    US
    PBM
    +0.68%

    Morning Trend | Psyence Biomedical continues to see reduced volume with no interest, will sudden topics disrupt the rebound?

    Psyence Biomedical (PBM.US) has recently continued to consolidate with decreasing volume, and the intraday trading has been extremely quiet, reaching a level of minimal activity. The atmosphere in the community is noticeably cold—“no one dares to act, and the colder it gets, the more likely it is to be the eve of a thematic explosion.” Traders are silently waiting for a spark, or a small rebound ignited by emotions. There are currently no significant company catalysts in the news, but similar biotech stocks in the sector have shown unusual movements, and some short-term speculative themes are showing signs of correlation. If there is a sudden thematic stimulus (such as research and development progress, industry mergers and acquisitions, regulatory easing, etc.), the typically quiet small-cap stocks can easily experience a rebound pulse driven by major players. Technically, the current low volatility in intraday trading combined with low-level daily candlesticks indicates that the more extreme the minimal trading volume, the more it is worth waiting for sudden capital movements. In terms of operations, ultra-short players should pay attention to the "first bearish engulfing" signal and intraday volume anomalies. It is recommended to maintain a low position and watch for sudden changes in market direction during the day; any unusual capital movements on the limit-up board could serve as a signal to ignite the entire market. If the follow-up buying quickly expands after a high opening, the daily increase could double in an instant. In summary: Psyence Biomedical is currently in a period of extreme market indifference, and the quiet small-cap stocks are likely to present opportunities for emotional pulses. Once a sudden thematic spark ignites, major players may accumulate and push prices higher, signaling the arrival of a rebound window. Traders are quietly waiting for the moment when market emotions become uncontrollable, and seizing the first wave of unusual movements is the opportunity to profit from such stocks

    Technical Forecast·
    US
    PBM
    +0.68%
    Technical Forecast·
    US
    PBM
    +0.68%

    Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

    NEW YORK, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Psyence Biomedical Ltd. ( Nasdaq: PBM ) ( "Psyence BioMed" or the "Company" ) , a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable ...

    GlobeNewswire·
    US
    PBM
    +0.68%
    GlobeNewswire·
    US
    PBM
    +0.68%
    © 2025 Longbridge｜Disclaimer